Reported about 1 year ago
TaiGen Life Sciences (6589) benefited from increasing CDMO orders, with shipments strengthening and May revenue reaching 120 million yuan, a 129% year-on-year increase. On June 11, foreign investors bought 657 shares, driving the stock price to hit the daily limit early at 86.3 yuan, marking a new high in two months with a high trading volume of 4,198 shares. The market expects further positive momentum and future growth potential. TaiGen Life Sciences is developing Herceptin biosimilar drug EG12014 for breast cancer treatment, with an impending US FDA approval expected in the second half of the year. The company also has opportunities for licensing out its second-generation drug EG1206A before the end of the year.
Source: YAHOO